Kindred Biosciences is a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets. Co.'s portfolio includes: Mirataz®, which is its transdermal drug for the management of weight loss in cats; and Zimeta™, which is for the control of pyrexia in horses. Co.'s product candidates include: KIND-016, a fully caninized monoclonal antibody targeting interleukin-31 for the treatment of atopic dermatitis in dogs; KIND-032, a fully caninized monoclonal antibody targeting interleukin-4 (IL-4) receptor for the treatment of atopic dermatitis in dogs; and KIND-025, a canine fusion protein targeting IL-4 and IL-13, for the treatment of atopic dermatitis in dogs. We show 35 historical shares outstanding datapoints in our KIN shares outstanding history coverage, used to compute KIN market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing KIN market cap history over the course of time is important for investors
interested in comparing KIN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of KIN versus a peer is one thing; comparing
KIN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like KIN can fluctuate over the course of history.
With this page we aim to empower investors researching KIN by allowing them to research the KIN market cap history. |
Free KIN Email Alerts:
Video: The Importance of Market Cap
